|
**Overview**: Gastro Health Panel**Introduction**: The Gastro Health Panel is a diagnostic tool designed to assess gastrointestinal health using serum samples. In India, GI disorders (H. pylori gastritis, peptic ulcer, GERD, IBD) affect ~20-30 percent of adults, with H. pylori prevalence ~60-80 percent in rural/low-SES populations contributing to gastric cancer risk. High morbidity from under-testing leading to delayed eradication therapy or endoscopy, limited labs, causing chronic dyspepsia, bleeding, or malignancy. Per gastroenterology practices aligned with ICMR and Indian Society of Gastroenterology guidelines, the test employs spectrophotometry/immunoassay for H. pylori IgG, pepsinogen I/II, gastrin, amylase, lipase, CRP, ESR, and CBC over 1-2 days with high accuracy, valuable for non-invasive gastritis screening and risk stratification (low pepsinogen I/II ratio indicates atrophy). This diagnostic falls under GI screening and targets patients with dyspepsia, reflux, or family cancer history, addressing accurate detection to guide PPI, eradication, or endoscopy referral. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling serum-based GI profiling and reducing gastric disease burden. Its serum-based approach ensures reliable inflammatory/serologic assessment.**Other Names**: Gastro Health Pnl.**FDA Status**: FDA approved, CLIA certified for biochemistry/endocrinology/immunology, compliant with 2025 standards.**Historical Milestone**: Pepsinogen/H. pylori serology standard in gastric cancer screening; in India, used in dyspepsia workup.**Purpose**: The test assesses 9 parameters including H. pylori IgG to guide GI health screening, detect inflammation/atrophy, inform therapy.**Test Parameters**: 1. H. pylori IgG, 2. Pepsinogen I, 3. Pepsinogen II, 4. Gastrin, 5. Amylase, 6. Lipase, 7. CRP, 8. ESR, 9. CBC.**Pretest Condition**: Fasting 10-12 hours recommended; patients should have GI symptoms.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on dyspepsia, reflux, family cancer.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undetected GI pathology including cancer, benefits of screening, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using spectrophotometry/immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive H. pylori + low PGI/II ratio indicates atrophy risk; elevated CRP/ESR suggests inflammation, necessitating specialist input.**Specialist Consultation**: Gastroenterologists should be consulted for management.**Additional Supporting Tests**: Urea breath test, endoscopy for confirmation.**Test Limitations**: Serology not for active infection; comprehensive approach required.**References**: Indian Journal of Gastroenterology 2024, GI Studies India 2023. |
